Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Adaptive Biotechnologies is a member of the Medical sector. This group includes 1010 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).Over the past three months, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 8.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.According to our latest data, ADPT has moved about 15.4% on a year-to-date basis. In comparison, Medical companies have returned an average of -3.8%. This means that Adaptive Biotechnologies is performing better than its sector in terms of year-to-date returns.Another stock in the Medical sector, Bio-Rad Laboratories (BIO), has outperformed the sector so far this year. The stock's year-to-date return is 4.9%.In Bio-Rad Laboratories' case, the consensus EPS estimate for the current year increased 2.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Breaking things down more, Adaptive Biotechnologies is a member of the Medical - Biomedical and Genetics industry, which includes 512 individual companies and currently sits at #56 in the Zacks Industry Rank. On average, this group has lost an average of 13.6% so far this year, meaning that ADPT is performing better in terms of year-to-date returns.In contrast, Bio-Rad Laboratories falls under the Medical - Products industry. Currently, this industry has 82 stocks and is ranked #77. Since the beginning of the year, the industry has moved +14.1%.Adaptive Biotechnologies and Bio-Rad Laboratories could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Adaptive Biotechnologies Corporation (ADPT): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks